Trial Profile
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Tivantinib (Primary)
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms METIV-HCC
- Sponsors Daiichi Sankyo Company
- 03 Apr 2018 Results assessing safety and efficacy published in the Lancet Oncology
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 17 May 2017 According to an ArQule media release, data from this strial will be presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.